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Introduction
Contrast induced nephropathy is one cause of acute kidney 
failure. Contrast induced nephropathy is the third most 
common cause of hospital-acquired acute renal failure (1). 
The incidence of contrast induced nephropathy in the general 
population is 0.6% to 2.3%, but when focusing on specific high-
risk patients the incidence can increase to more than 40% (1,2).
Contrast induced nephropathy is  associated with an increased 
risk of prolonged hospital stay, increased risk of nosocomial 
complications, potential need for dialysis, increased health care 
costs and mortality (1-3).
Identification of patients potentially susceptible of developing 
contrast induced nephropathy before their exposure is 
important, since modification of the ways we administer 
contrast medium can lead to a decrease in acute kidney 
injury (1-4).
Diagnosis of contrast induced nephropathy is most often based 
on an increase in the serum level of creatinine after exposure to 
a contrast agent. 
Diagnostic criteria for contrast-induced nephropathy
1. Exposure to contrast agent.
2. Increase in serum level of creatinine of 0.5 mg/dl or 25% 
greater than baseline.
3. Increase in serum level of creatinine occurs 48-72 hours 
after administration of contrast agent and persists for 2-5 
days.
4. Alternative major injuries are ruled out.
Risk factors 
Addressing and resolving modifiable risk factors before 
administration of contrast agents decrease a patient’s risk of 
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contrast induced nephropathy (2-5).
Risk factors for development of contrast-induced nephropathy 
are; Dehydration, hyperosmolar media, administration of 
>100 mL of contrast media, recent administration of contrast 
media, hypotension, use of nephrotoxic agents, anemia, shock, 
sepsis, use of intra-aortic balloon pump,  preexisting  kidney 
impairment, diabetes, ventricular dysfunction: ejection fraction 
<40%, hypercholesterolemia and  age >75 years (3-6).
Patients with existing impaired renal function or diabetes 
mellitus (type 1 and type 2) are at the highest risk.
Diabetes mellitus putatively predisposes host kidneys to 
ischemic injury (from macro- or micro-vascular stenosis), 
increases oxidative stress and free radical damage, as well 
as endothelial dysfunction. In addition to the impact of a 
baseline diabetes mellitus, pre-procedural glucose level higher 
than 200 mg/dl, is also a risk factor for contrast-induced 
nephropathy (2-7).
Advanced age is another risk factor that enhances the probability 
of developing contrast-induced nephropathy. Age higher than 
75 can associate with a 1.5-5 fold elevated risk, while every one-
year increment carries a 2% increased risk.
The physiologic degeneration of the kidney which named as 
aging kidney, both structurally and functionally, and the ability 
of recovery after various nephrotoxic insults also dampens in 
this population (5-9).
One-third of patients with serum creatinine level higher than 
2.0 mg/dl receiving contrast media for radiographic studies will 
develop contrast-induced nephropathy (1-7).
Hemodynamic instability and anemia are as a factor that 
reduces tissue oxygenation and predisposes to contrast-induced 
nephropathy (2-7).
The most common procedures associated with contrast-
induced nephropathy are coronary angiography and contrast-
enhanced computed tomography. Patients who undergo 
coronary angiography are at highest risk for contrast-induced 
nephropathy. Often the procedure is done under emergent 
conditions, and patients may be volume depleted, and their 
hemodynamic status may be less than optimal (3-9).
Congestive heart failure (grade 3-4) is associated with elevated 
risk of contrast-induced nephropathy use of angiotensin-
converting-enzyme inhibitors or angiotensin receptor blockers 
is associated with 2.5-3.0 fold higher risk of developing 
contrast-induced nephropathy after coronary angiography. On 
the contrary, withdrawal of angiotensin-converting-enzyme 
inhibitor or angiotensin receptor blocker before coronary 
procedures does not seem to reduce the risk of contrast-induced 
nephropathy (1-5).
Other nephrotoxic substances including; nonsteroidal 
anti-inflammatory drugs, calcineurin inhibitors, loop 
diuretics, aminoglycosides, amphotericin B, vancomycin, 
chemotherapeutic agents and metformin (6-9).
Even small volumes of contrast media (~30 ml) might trigger 
kidney injury in high-risk patients. For every 100 ml increase 
in the amount of contrast media used, there is a concomitant 
12% increase of the risk. Adjustment of the contrast volume to 
one’s body weight and serum creatinine level could minimize 
the risk (8,9).
Intra-arterial injection of contrast media carries a higher 
risk of contrast-induced nephropathy than intravenous use. 
However, no mechanisms have been provided to explain this 
phenomenon. Some reasons are as the dose used in intravenous 
enhancement for computed tomography (CT) is usually lower 
than that for arteriography; patients who received contrast-
enhanced CT are usually less hemodynamically unstable than 
ones receiving intra-arterial (2-9).
Pathogenesis
The pathogenesis of contrast-induced nephropathy is not clear. 
Studies suggest that contrast-induced nephropathy, is due to a 
combination of toxic and ischemic injury to the kidney tubular 
cells. Proximal and distal tubular injury occurs at the moment 
of contact with contrast media and is thought to be due to an 
interplay of intrarenal vasoconstriction, medullary hypoxia, 
and direct tubular cell death (3-9).
Mechanisms underlying contrast-induced nephropathy, 
include direct cytotoxic effects, auto-, and paracrine factors that 
perturb kidney hemodynamics, altered rheological properties 
that affect kidney hemodynamics and tubulodynamics, and 
regional hypoxia (2-8).
Contrast media intravascular injection can increase the activity 
of a variety of vasoactive substances, including vasopressin, 
angiotensin II, dopamine-1, endothelin and adenosine, while 
decrease the activity of renal vasodilators such as nitric oxide 
and prostaglandins (3-10).
Patients with diabetes and kidney failure have an increased 
risk for contrast-induced nephropathy, because of a reduction 
in endogenous vasodilators such as nitric oxide and 
prostaglandins, which results in a decrease in kidney blood 
flow and glomerular filtration rate (2-9).
Contrast agents may trigger the release of endothelin and 
adenosine from endothelial cells, increasing vasoconstriction, 
and decrease the release of prostaglandins, preventing 
vasodilatation, hence, decreasing oxygen in the outer medulla. 
Impairment in flow leads to hypoxia and decreased nutrient 
delivery to tubular epithelial cells, resulting in increases in 
reactive oxygen species, causing breakdown of the epithelial 
cyto-structure with loss of cell parity and death of the cell (3-8).
Length of exposure to a contrast agent is related to the extent 
of damage of kidney tubular cells. Contrast agents are thought 
to produce prolonged vasoconstriction of the arteriole and 
stasis of contrast material in the renal vasculature, resulting 
in medullary ischemic injury and death of proximal and distal 
kidney tubular cells (1-5).
The osmolality of contrast media may play a role in the 
pathogenesis of contrast-induced nephropathy. A relationship 
exists between osmolality and viscosity, thereby increasing 
the resistance to flow in kidney tubules. High osmolal agents 
diminish the deformability of erythrocytes, thereby increasing 
the cells’ stiffness and making the flow of red blood cells 
through the capillaries more difficult (8-12).
Hypovolemia triggers physiological countermeasures aiming 
at volume preservation, especially, activation of the renin-
angiotensin system and of vasopressin. Angiotensin II 
and vasopressin augment tubular fluid resorption, which 
diminishes urine flow rate. In addition, angiotensin II elicits 
kidney vasoconstriction, which aggravates contrast media 
induced medullary hypoperfusion (4-10).
The tubular toxicity of contrast medium can be demonstrated 
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in the pathological changes it induces, consisting epithelial 
vacuolization, apoptosis, cellular necrosis and interstitial 
inflammation. Contrast media can additionally reduce 
antioxidant enzyme activity within the kidney, and free radical 
mediated cytotoxicity of the renal tubular cells has been 
detected in these models (2-8).
Prevention 
Patients with hypertension, congestive heart failure, diabetes 
mellitus or potentially changing renal function should receive 
a baseline renal function testing, and if possible, a nephrology 
consultation could be obtained (3-7).
Hyperglycemic status should be properly managed before 
administration of contrast media. Agents such as nonsteroidal 
anti-inflammatory drugs, diuretics, and possibly angiotensin-
converting-enzyme inhibitors should be discontinued 1-2 days 
before administration of contrast media (1-7).
The amount of contrast media volume should be as little as 
possible, and the choice of contrast media should be iso-
osmolar or low osmolar agents (1-5).
This cytotoxic effect does not seem to be caused by iodine or 
osmolality lesser than 830 mosm/L (5-9).
 The goal of prevention is to protect the renal tubules from 
prolonged contact with contrast material, because permanent 
damage can occur at the time of contact (2-8).
Repeated exposure should be delayed for 48 hours in patients 
at-risk of developing contrast-induced nephropathy (1-6).
Studies suggest that intravenous hydration is the most effective 
strategy to prevent contrast-induced nephropathy. Hydration 
is inexpensive and is usually risk-free. Administration of 
optimal fluids before and after the contrast procedure allows 
for increased urine output and improved outcomes (1-8).
The benefit of adequate volume expansion includes improving 
renal blood flow, inducing diuresis with dilution of contrast 
media within kidney tubules, suppression of the renin-
angiotensin-aldosterone system, and less reductions in the 
kidney production of endogenous vasodilators (3-9).
Intravenous hydration is more favorable than oral hydration. 
The most effective solution for preventing of contrast-induced 
nephropathy is isotonic saline (0.9%).
No benefit from forced diuresis with intravenous crystalloid, 
furosemide, mannitol or low dosed dopamine therapy, 
compared with hydration alone in at-risk patients. Isotonic 
hydration is superior to half-isotonic hydration in the 
efficacy for prevention of contrast-induced nephropathy. It is 
recommended now that intravenous hydration should start 12 
hours before and continue for 12 hours after (2-9).
Two strategies are available to prevent an acidic environment 
and formation of free radicals in the renal tubules: sodium 
bicarbonate and N-acetylcysteine. N-acetylcysteine increases 
production of nitric oxide, which has vasodilatory capabilities, 
and the concentration of glutathione, which acts as a free 
radical scavenger. Compared with infusion of normal saline 
alone, administration of N-acetylcysteine in conjunction with 
infusions of normal saline significantly decreased the risk for 
contrast-induced nephropathy (3-11).
The most common protocol of N-acetylcysteine is to give this 
agent orally 600 mg twice a day for 24 hours on the day before 
and the day of procedure (3-11).
Sodium bicarbonate may result in urine alkalinization and 
reduce the generation of free radical through scavenging 
reactive oxygen species (3-7).
Fenoldopam mesylate is a selective dopamine-1 receptor agonist 
that produces systemic and kidney artery vasodilatation. It 
is found to exhibit desirable renal effects including decrease 
in renal vascular resistance and increase in renal blood flow, 
glomerular filtration rate, with natriuresis. The routine use of 
fenoldopam to protect against contrast-induced nephropathy 
could not be recommended (2-7). Other agents such as 
ascorbic acid, theophylline, statin can be used to protect of 
contrast-induced nephropathy but these agents routinely not 
recommended.
Conclusion
Contrast induced nephropathy is one cause of acute renal 
failure.  Contrast induced nephropathy is the third most 
common cause of hospital-acquired acute renal failure. The 
incidence of contrast induced nephropathy in the general 
population is 0.6% to 2.3%, but when focusing on specific 
high-risk patients the incidence can increase to more than 40%. 
Studies suggest that intravenous hydration is the most effective 
strategy to prevent contrast induced nephropathy. Hydration is 
inexpensive and is usually risk-free. The goal of prevention is to 
protect the renal tubules from prolonged contact with contrast 
material, because permanent damage can occur at the time 
of contact. Administration of optimal fluids before and after 
the contrast procedure allows for increased urine output and 
improved outcomes.
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